Media Thread, page-13422

If any offer is made, the good news is that it will be BP that sets the initial offer price, not shareholders, and they would better understand fair value. And if you're in this for the end game, the share price today means nothing until that offer is made.

The problem is that most investors can not see the forest from the trees when it comes to the trial results. I'm sure there will be some that will review the results of the dose escalation studies with a lens focused on proportion increase of CR vs SD and tell you fail if there isn't some staggering rate of increase in CRs as the doses get higher.

At this stage of the game, SD is fantastic. Not only are we providing a response and control of cancer in patients that have failed multiple lines of treatment. But we have done so with few side effects and amazing safety.

That patients cancer was successfully targeted only provides further evidence in the support of Oncarlytics.

Similarly, the result for the Cholangiocarcinoma patients, is outstanding given the overall low survival rate and unmet need. The FDA fast track designation for Bile Duct cancer patients is validation of the results and so much less a study based on hope.

Another word bandied around often is Standard of Care. I'm sure many think on this from a lens of replacing chemo, replacing other curative drugs that have a myriad of nasty side effects, replacing the need of invasive surgery to excise cancer laden tissue, organs etc.

Sad part is that cancer rates increase as people get older and there is certainly a point reached where health care providers look at the patients' age and consider quality / extension of life over the harsher options or invasive procedures that might offer a chance of a cure.

In all this, I am extremely positive about Imugene's prospects, but I am really thankful and hopeful for the patients and their families that are supportive of them taking part in the trials.